Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + HLX04
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Serplulimab + HLX04 is a combination therapy developed by Shanghai Henlius Biotech. It consists of serplulimab (HLX10), a fully humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor, and HLX04 (HANBEITAI), a biosimilar of bevacizumab that targets vascular endothelial growth factor (VEGF). This combination leverages the synergistic effects of immune checkpoint inhibition and anti-angiogenesis to enhance anti-tumor activity. By blocking PD-1, serplulimab restores T-cell mediated immune responses against tumor cells, while HLX04 inhibits VEGF-mediated tumor vasculature growth and normalizes the tumor microenvironment, potentially improving the infiltration of immune cells. The combination is being investigated for various solid tumors, including advanced hepatocellular carcinoma, metastatic colorectal cancer, and non-squamous non-small-cell lung cancer.
- Brand names
- HANSIZHUANG + HANBEITAI
- Other names
- serplulimab + bevacizumab biosimilar斯鲁利单抗 + 汉贝泰serplulimab + HLX04-Shanghai Fuhong Hanlin-PD-1-VEGF-combination therapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on serplulimab + HLX04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + HLX04.